Chargement en cours...
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway
In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy. To explore the potential procarcinogenic role of this ERBB2 mutation, we conducted the present study using BC cells overexpressing wild...
Enregistré dans:
| Publié dans: | Biol Open |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Company of Biologists Ltd
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6994922/ https://ncbi.nlm.nih.gov/pubmed/31980423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/bio.047662 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|